Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could 5 days of antibiotics cut infections after pancreatic surgery?

NCT ID NCT06123169

First seen Feb 06, 2026 · Last updated Jun 21, 2026 · Updated 18 times

Summary

This study compares two antibiotic strategies in 326 adults undergoing pancreatic surgery who had a bile duct stent placed before surgery. One group gets antibiotics only during surgery, the other gets them for 5 days after. The goal is to see if the longer course reduces surgical site infections, including pancreatic leaks. The trial is not yet recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATICODUODENECTOMY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de ROUEN

    Rouen, 76031, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Piperacillin-tazobactam (an antibiotic)

What this could lead to

If successful, this could establish a standard antibiotic regimen to prevent serious infections after pancreatic surgery in patients with a prior bile duct stent.

What could go wrong

This is a Phase 3 trial, but it has not yet started recruiting. The benefit may be small, and antibiotics carry risks like allergic reactions or drug-resistant infections.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.